Bevacizumab and interferon reduce venous recanalization following sclerotherapy

The treatment of venous malformations is difficult because these lesions frequently recur after resection or sclerotherapy. The purpose of this study was to determine whether recanalization of sclerosed venous lumens could be prevented with systemic angiogenic inhibition using bevacizumab or peginterferon alfa-2a.

Source: Journal of Pediatric Surgery - August 25, 2016 Category: Surgery Authors: Ann M. Kulungowski, Aladdin H. Hassanein, Carolyn C. Foster, Arin K. Greene, Steven J. Fishman Source Type: research